The estimated Net Worth of Bros. Advisors Lp667, L.P.B... is at least $876 Milion dollars as of 20 August 2024. Bros B owns over 1 units of Prelude Therapeutics Inc stock worth over $27,584,930 and over the last 7 years Bros sold PRLD stock worth over $848,420,795.
Bros has made over 43 trades of the Prelude Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Bros bought 1 units of PRLD stock worth $46 on 20 August 2024.
The largest trade Bros's ever made was buying 5,814,100 units of Prelude Therapeutics Inc stock on 2 August 2018 worth over $627,922,800. On average, Bros trades about 321,496 units every 22 days since 2018. As of 20 August 2024 Bros still owns at least 5,516,986 units of Prelude Therapeutics Inc stock.
You can see the complete history of Bros B stock trades at the bottom of the page.
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita a Advisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include: